257 related articles for article (PubMed ID: 7680400)
21. Tumour infiltrating plasmacytoid dendritic cells in B cell post-transplant lymphoproliferative disorders, human immunodeficiency virus-associated B cell lymphomas and immune competent diffuse large B cell lymphomas.
Ibrahim HA; Menasce L; Pomplun S; Burke M; Bower M; Naresh KN
Histopathology; 2011 Jul; 59(1):152-6. PubMed ID: 21771035
[No Abstract] [Full Text] [Related]
22. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
Guilloux Y; Viret C; Gervois N; Le Dréan E; Pandolfino MC; Diez E; Jotereau F
Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155
[TBL] [Abstract][Full Text] [Related]
23. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.
Agrawal S; Marquet J; Delfau-Larue MH; Copie-Bergman C; Jouault H; Reyes F; Bensussan A; Farcet JP
J Clin Invest; 1998 Nov; 102(9):1715-23. PubMed ID: 9802885
[TBL] [Abstract][Full Text] [Related]
24. T-cell recognition of ovarian cancer.
Peoples GE; Schoof DD; Andrews JV; Goedegebuure PS; Eberlein TJ
Surgery; 1993 Aug; 114(2):227-34. PubMed ID: 8342128
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
26. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
[TBL] [Abstract][Full Text] [Related]
28. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
[TBL] [Abstract][Full Text] [Related]
29. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
30. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
31. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA
J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379
[TBL] [Abstract][Full Text] [Related]
32. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression.
Kataki A; Scheid P; Piet M; Marie B; Martinet N; Martinet Y; Vignaud JM
J Lab Clin Med; 2002 Nov; 140(5):320-8. PubMed ID: 12434133
[TBL] [Abstract][Full Text] [Related]
33. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.
Pandolfino MC; Viret C; Gervois N; Guilloux Y; Davodeau F; Diez E; Jotereau F
Eur J Immunol; 1992 Jul; 22(7):1795-802. PubMed ID: 1623924
[TBL] [Abstract][Full Text] [Related]
34. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
35. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH
Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363
[TBL] [Abstract][Full Text] [Related]
36. Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin's lymphomas.
Chaperot L; Delfau-Larue MH; Jacob MC; Molens JP; Roussel B; Agrawal S; Farcet JP; Gressin R; Sotto JJ; Bensa JC; Plumas J
Exp Hematol; 1999 Jul; 27(7):1185-93. PubMed ID: 10390194
[TBL] [Abstract][Full Text] [Related]
37. Patterns of costimulation of T cell clones by cross-linking CD3, CD4/CD8, and class I MHC molecules.
Wacholtz MC; Patel SS; Lipsky PE
J Immunol; 1989 Jun; 142(12):4201-12. PubMed ID: 2470819
[TBL] [Abstract][Full Text] [Related]
38. Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors.
Miescher S; Stoeck M; Qiao L; Barras C; Barrelet L; von Fliedner V
Cancer Res; 1988 Dec; 48(24 Pt 1):6992-8. PubMed ID: 3263897
[TBL] [Abstract][Full Text] [Related]
39. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
Zeng G
J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
[TBL] [Abstract][Full Text] [Related]
40. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.
Yamada N; Oizumi S; Kikuchi E; Shinagawa N; Konishi-Sakakibara J; Ishimine A; Aoe K; Gemba K; Kishimoto T; Torigoe T; Nishimura M
Cancer Immunol Immunother; 2010 Oct; 59(10):1543-9. PubMed ID: 20567822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]